Lack of Hepatotoxicity Associated With Nonnucleoside Reverse Transcriptase Inhibitors

Palmon, Ron; Koo, Bon Chang A.; Shoultz, David A.; Dieterich, Douglas T.

doi:10.1097/00042560-200204010-00003

Cited by 18 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a study done in New York City, USA had similar results to our findings with mild toxicity (grade 1 and 2) of 16.7% and severe toxicity (grade 3 and 4) of 1.4% [10]. Lower results were also found in a study conducted in Tanzania which found 0.3% severe hepatotoxicity [1] while a higher prevalence of 7% was found in a study done in Cameroon in mono-infected patients [18].…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Serum Alanine Aminotransferase Elevations in HIV Positive Patients on Antiretroviral Therapy in Namibia

Shanyengana¹,

Mukesi²,

Colf³

et al. 2016

WJA

View full text Add to dashboard Cite

Elevated alanine aminotransferase (ALT) levels in Human Immunodeficiency Virus (HIV) infected people is a major concern in the world and especially in Africa. It may lead to liver failure and even death. Certain antiretroviral (ARV) drugs, such as nevirapine and efavirenz, are known to cause toxicity. Other causes of elevated ALT are viral hepatitis, the HIV virus itself and other drugs such as anti-tu-berculosis drugs and alcoholism. The study aimed at determining the prevalence of elevated ALT levels in HIV positive patients on antiretroviral therapy during the period 2013 to 2014. This was a retrospective study which included 267 patient records from Katutura and Windhoek Central hospitals in Windhoek, Namibia. The subjects' ages ranged from 21 to 82 years. The patients enrolled were on the first line treatment and their ALT levels were recorded at each monitoring period. ALT levels, viral hepatitis results and the antiretroviral therapy (ART) regimen were the most important aspects included in the study. Out of 267 patients, 18% had ALT elevation associated with grade 1 to 4 toxicity levels. The study found that 1.4% of patients developed severe liver toxicity (grade 3 and 4 toxicity). Toxicity occurred throughout the treatment period but was the highest at six months of treatment. Patients on nevirapine based regimens had lower toxicity compared to those receiving efavirenz based regimens. Patients who had HIV and viral hepatitis co-infection had high toxicity although the study found no severe hepatotoxicity in these patients.

show abstract

Section: Discussionsupporting

confidence: 89%

“…A retrospective cohort study that determined the incidence of NNRTI hepatotoxicity in a group of HIV-infected patients in New York City practice found that grade 3 -4 elevations in ALT and/or AST levels occurred in 3 (1.1%) of 272 patients [10].…”

mentioning

confidence: 99%

Serum Alanine Aminotransferase Elevations in HIV Positive Patients on Antiretroviral Therapy in Namibia

Shanyengana¹,

Mukesi²,

Colf³

et al. 2016

WJA

View full text Add to dashboard Cite

show abstract

“…This fact suggest that the severity of liver damage could be the most important factor in explaining the risk of toxicity for a significant proportion of NNRTI-treated patients, and therefore, this group of patients should be monitored more closely if a decision to initiate treatment with drugs from this class is made. In addition, the importance of the severity of liver damage could explain the contradictory data among different studies when considering the rate of liver toxicity among NNRTItreated patients [32][33][34].…”

Section: Discussionmentioning

confidence: 99%

Influence of Liver Fibrosis on Highly Active Antiretroviral Therapy--Associated Hepatotoxicity in Patients with HIV and Hepatitis C Virus Coinfection

Aranzabal

Casado

Moya

et al. 2005

Clinical Infectious Diseases

126

View full text Add to dashboard Cite

show abstract

“…[88][89][90][91] However, delayed onset of symptoms can be seen up to 8 weeks following discontinuation of therapy [89,91] and prolonged cholestasis with ductopenia following cessation of therapy has also been reported. [92] A recent large prospective case series involving 69 patients with amoxicillin-clavulanate hepatotoxicity suggested that the type of hepatic injury observed varies according to the time from onset of therapy, where hepatocellular injury predominates at 1 week, cholestatic injury at 2-3 weeks and mixed liver injury after 3 weeks.…”

Section: Amoxicillin-clavulanic Acidmentioning

confidence: 99%

A Review on Drug Induced Hepatotoxicity and Its Management by Herbal Drugs

Singh¹

2017

WJPPS

View full text Add to dashboard Cite

The liver plays vital functions in maintaining, performing and regulating the homeostasis of body and it involves in almost all biochemical pathways such as nutrient supply, reproduction, biotransformation, energy supply and growth. The liver metabolize, detoxify and activate exogenous as well as endogenous compound and is capable for transforming foreign chemicals as it has high level of enzymatic system. Liver disorder or injury is defined as conditions, diseases, or infections that influence the structure and/or function of

show abstract

Lack of Hepatotoxicity Associated With Nonnucleoside Reverse Transcriptase Inhibitors

Cited by 18 publications

References 8 publications

Serum Alanine Aminotransferase Elevations in HIV Positive Patients on Antiretroviral Therapy in Namibia

Serum Alanine Aminotransferase Elevations in HIV Positive Patients on Antiretroviral Therapy in Namibia

Influence of Liver Fibrosis on Highly Active Antiretroviral Therapy--Associated Hepatotoxicity in Patients with HIV and Hepatitis C Virus Coinfection

A Review on Drug Induced Hepatotoxicity and Its Management by Herbal Drugs

Contact Info

Product

Resources

About